Treatment of chronic fistula-in-ano using commercial fibrin glue.

Abdulmajeed Al-Abdulkareem

2004-08-01

Saudi Medical Journal

Abstract:

What problem does this paper attempt to address?

In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions

P. Sittiwattanawong,K. Kantikosum,K. Charoenchaipiyakul,S. Pootongkam,P. Asawanonda,S. J. Kerr,P. Thantiworasit,P. Sodsai,N. Hirankarn,J. Klaewsongkram,P. Rerknimitr

DOI: https://doi.org/10.1111/1346-8138.17207

IF: 3.468

2024-04-13

The Journal of Dermatology

Abstract:Drug causality assessment in severe cutaneous adverse reactions (SCARs) remains challenging. We investigated the usefulness of in‐vivo drug patch tests (PT), ex‐vivo interferon (IFN)‐γ enzyme‐linked immunospot (ELISpot) assay, and lymphocyte transformation test (LTT) in 30 SCARs patients within the past 36 months. Drug PT yielded a 20% positivity rate (n = 6), while IFN‐γ ELISpot and LTT showed positive rates of 56.67% (n = 17) and 41.38% (n = 12), respectively. Combining the three tests resulted in an overall positive rate of 66.67% (n = 20) of cases. IFN‐γ ELISpot offered additional positivity, especially with oxypurinol. Employing a combined diagnostic approach may enhance the chances of obtaining a positive result.

dermatology
Delayed Skin Testing for Systemic Medications: Helpful or Not?

Annick Barbaud,Margarida Goncalo,Maja Mockenhaupt,Ana Copaescu,Elizabeth J Phillips

DOI: https://doi.org/10.1016/j.jaip.2024.06.047

2024-07-06

Abstract:Cutaneous adverse drug reactions collectively are delayed drug reactions such as morbilliform drug eruption and severe cutaneous adverse reactions (SCARs). Morbilliform drug eruption may wane over time, be the result of drug viral interactions, and be amenable to slow reintroduction or rechallenge, whereas SCARs are HLA class I restricted, T-cell-mediated reactions that demonstrate durable immunity and warrant lifelong avoidance. SCARs such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome and toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption often occur in the setting of multiple drugs dosed together. Collectively, they lead to significant morbidity, mortality, and drug safety concerns that could severely limit future treatment options. Currently, no single or combination of diagnostic tests for SCARs such as ex vivo or in vitro testing, in vivo (skin) testing, or other adjunctive tests such as HLA typing have 100% negative predictive value. In this "Controversies in Allergy Review" article, we review the current literature on delayed skin testing (patch and delayed prick/intradermal test) and critically assess the evidence base of its utility across different drugs and clinical phenotypes of delayed hypersensitivity reactions.
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

Teresa Bellón

DOI: https://doi.org/10.1007/s40264-019-00825-2

2019-04-24

Drug Safety

Abstract:Cutaneous adverse drug reactions are unpredictable and include various different skin conditions of varying degrees of severity. The most concerning are usually referred to as severe cutaneous adverse reactions (SCARs) and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS) or hypersensitivity syndrome (HSS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). All are delayed type IV hypersensitivity reactions in which a T-cell-mediated drug-specific immune response is responsible for causing the disease. Nonetheless, specific T-cell subpopulations develop in response to certain environmental conditions and produce cytokines that orchestrate the various phenotypes. Cytotoxic T lymphocytes (CTLs), T-helper type 1 (Th1), Th2, Th17, and regulatory T cells (Treg), among other T-cell subpopulations, participate in the development of SCAR phenotypes. Cell subpopulations belonging to the innate immune system, comprising natural killer cells, innate lymphoid cells, monocytes, macrophages and dendritic cells, can also participate in shaping specific immune responses in various clinical conditions. Additionally, tissue-resident cells, including keratinocytes, can contribute to epidermal damage by secreting chemokines that attract pro-inflammatory immunocytes. The final phenotypes in each clinical entity result from the complex interactions between a variety of cell lineages, their products, soluble mediators and genetic and environmental factors. Although the pathophysiology of these reactions is not fully understood, intensive research in recent years has led to major progress in our understanding of the contribution of certain cell types and soluble mediators to the variability of SCAR phenotypes.

pharmacology & pharmacy,public, environmental & occupational health,toxicology
Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology

Romane Cadot,Perrine Gery,Vanina Lenief,Jean-François Nicolas,Marc Vocanson,Marie Tauber

DOI: https://doi.org/10.1111/all.16316

IF: 12.4

2024-09-18

Allergy

Abstract:Severe cutaneous adverse reactions to drugs (SCARs) are rare but life-threatening delayed allergies. While they primarily affect the skin, they can also affect internal organs. Accordingly, they present with diverse clinical symptoms that vary not only between SCARs subtypes but also among patients. Despite the availability of topical and systemic treatments, these only address the symptoms and not the cause. To develop more effective therapies, it is necessary to elucidate the complexity of the pathophysiology of SCARs in relation to their severity. In line with the new type IV hypersensitivity reactions nomenclature proposed by the European Academy of Allergy and Clinical Immunology (EAACI), this review highlights the current insights into the intricate immune mechanisms engaged, the interplay between the culprit drug and genetic predisposition in drug presentation mechanisms, but also how external factors, such as viruses, are implicated in SCARs. Their relevance to the development of targeted medicine is also discussed.
Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

Chih-Jung Chang,Chun-Bing Chen,Shuen-Iu Hung,Chao Ji,Wen-Hung Chung

DOI: https://doi.org/10.3389/fphar.2020.00969

IF: 5.6

2020-07-02

Frontiers in Pharmacology

Abstract:Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over 30%, thus causing a major burden on the healthcare system. Recent pharmacogenomic studies have revealed strong associations between SCAR and the genes encoding human-leukocyte antigens (HLAs) or drug-metabolizing enzymes. Some of pharmacogenetic markers have been successfully applied in clinical practice to protect patients from SCAR, such as HLA-B*15:02 and HLA-A*31:01 for new users of carbamazepine, HLA-B*58:01 for allopurinol, and HLA-B*57:01 for abacavir. This article aims to update the current knowledge in the field of pharmacogenomics of drug hypersensitivities or SCAR, and its implementation in the clinical practice.

pharmacology & pharmacy
Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9‐year experience in a tertiary care paediatric hospital setting

Giulia Liccioli,Francesca Mori,Paola Parronchi,Manuela Capone,Lucia Fili,Simona Barni,Lucrezia Sarti,Mattia Giovannini,Massimo Resti,Elio M. Novembre

DOI: https://doi.org/10.1111/cea.13513

2019-10-28

Abstract:BackgroundSevere cutaneous adverse reactions (SCARs) are delayed‐type hypersensitivity reactions to drugs including: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens‐Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Acute Generalized Exanthematous Pustulosis (AGEP). Incidence, triggers and management of SCARs have not been investigated in large‐scale epidemiological studies on children. ObjectiveThe aim of our study was to collect epidemiological, clinical and etiological data from children with SCARs referred to our tertiary‐care paediatric hospital of Florence. MethodsFrom 2010 to 2018 charts of children with diagnosis of SCAR were reviewed and data collected during the acute phase and/or the subsequent allergy evaluation. Patients underwent patch tests, intradermal tests and lymphocyte transformation tests. All children were investigated for infectious diseases. ResultsIncidence of SCARs in hospitalized children was 0.32% over a 9‐year period. Fifty‐four children were enrolled (31 M; 23 F; median age 6.5 years): 17 cases of DRESS, 30 SJS, 3 TEN, 2 AGEP, 1 linear immunoglobulin‐A bullous disease (LABD) and 1 pemphigus. Twenty‐eight out of 54 patients underwent drug allergy investigations and 50% of them resulted positive. Combining clinical history and results of allergy work‐up, 74% SCARs seem to be caused by drugs, 18.6% by both drugs and infections, 3.7% by infections, 3.7% remained idiopathic. No deaths occurred. ConclusionsIn this study SCARs incidence is in line with literature data. Drugs were most commonly the leading cause. Management of SCARs requires cooperation among professional figures for an early diagnosis and a prompt treatment. Mortality rate seems to be lower in children.

immunology,allergy
Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist?

Sophie Bouvresse,Laurence Valeyrie-Allanore,Nicolas Ortonne,Marie Pauline Konstantinou,Sylvia H Kardaun,Martine Bagot,Pierre Wolkenstein,Jean-Claude Roujeau

DOI: https://doi.org/10.1186/1750-1172-7-72

2012-09-25

Orphanet Journal of Rare Diseases

Abstract:Abstract Background Severe cutaneous adverse reactions to drugs (SCARs) include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) and epidermal necrolysis (Stevens-Johnson syndrome–toxic epidermal necrolysis [SJS-TEN]). Because of the varied initial presentation of such adverse drug reactions, diagnosis may be difficult and suggests overlap among SCARs. Overlapping SCARs are defined as cases fulfilling the criteria for definite or probable diagnosis of at least 2 ADRs according to scoring systems for AGEP, DRESS and SJS-TEN. We aimed to evaluate the prevalence of overlap among SCARs among cases in the referral hospital in France. Methods We retrospectively analyzed data for 216 patients hospitalized in the referral centre over 7 years with a discharge diagnosis of AGEP (n = 45), DRESS (n = 47), SJS-TEN (n = 80) or “drug rash” (n = 44). Each case with detailed clinical data and a skin biopsy specimen was scored for AGEP, DRESS and SJS-TEN by use of diagnostic scores elaborated by the RegiSCAR group. Results In total, 45 of 216 cases (21%) had at least 2 possible diagnoses: 35 had a single predominant diagnosis (definite or probable), 7 had several possible diagnoses and 3 (2.1% of 145 confirmed SCARs) were overlap SCARs. Conclusions Despite ambiguities among SCARs, confirmed overlap cases are rare. This study did not avoid pitfalls linked to its retrospective nature and selection bias. In the acute stage of disease, early identification of severe ADRs can be difficult because of clinical or biologic overlapping features and missing data on histology, biology and evolution. Retrospectively analyzing cases by use of diagnostic algorithms can lead to reliable discrimination among AGEP, DRESS and SJS-TEN.

genetics & heredity,medicine, research & experimental
Medication Associations with Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System

Hannah Godfrey,Patrick Jedlowski,Rebecca Thiede

DOI: https://doi.org/10.1177/12034754231220931

2024-01-10

Journal of Cutaneous Medicine and Surgery

Abstract:Journal of Cutaneous Medicine and Surgery, Ahead of Print. Background:Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) are potentially life-threatening severe cutaneous adverse reactions (SCARs). Although the classical causal agents of SCARs (antibiotics, anticonvulsants, nonsteroidal anti-inflammatory drugs, and allopurinol) are well characterized, there has been little update to this list to account for newly marketed medications.Objective:To provide an updated and stratified list of medications with significant reporting odds ratios (RORs) of SCARs.Methods:A case/non-case analysis using the United States FDA Adverse Event Reporting System was performed.Results:As expected, the prototypical medication classes made up the majority of reported cases of SJS, TEN, AGEP, and DRESS (77%, 64%, 75%, and 72%, respectively). In addition, several infrequently or previously undescribed classes/medications implicated in SCARs were identified to have significant ROR signals, including acetylcysteine, anticoagulants, diuretics, immunotherapies, proton pump inhibitors, antivirals, and antifungals. Among these reported for SJS were acetylcysteine (ROR: 64.38) and fluconazole (ROR: 17.13). For TEN, we identified furosemide (ROR: 26.32), spironolactone (ROR: 14.45), fluconazole (ROR: 30.21), amphotericin B (39.06), and acetylcysteine (ROR: 93.12). For AGEP, we identified acyclovir (ROR: 61.72), valacyclovir (ROR: 30.76), and enoxaparin (ROR: 27.37). For DRESS, we identified vemurafenib (ROR: 17.35), acyclovir (ROR: 30.63), abacavir (ROR: 26.62), raltegravir (ROR: 23.27), and valacyclovir (ROR: 21.77) to have strong reporting odds.Conclusion:Our analysis provides an updated tool for physicians to reference when identifying suspected SCARs and a basis for future studies to investigate atypical medication causality.

dermatology
Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions

Mari Orime

DOI: https://doi.org/10.1155/2017/6928363

Abstract:Diagnosis of severe cutaneous adverse drug reactions should involve immunohistopathological examination, which gives insight into the pathomechanisms of these disorders. The characteristic histological findings of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) provide conclusive evidence demonstrating that SJS/TEN can be distinguished from EM. Established SJS/TEN shows full-thickness, extensive keratinocyte necrosis that develops into subepidermal bullae. Drug-induced hypersensitivity syndrome (DIHS) and exanthema in drug reaction with eosinophilia and systemic symptoms (DRESS) each display a variety of histopathological findings, which may partly correlate with the clinical manifestations. Although the histopathology of DRESS is nonspecific, the association of two or more of the four patterns-eczematous changes, interface dermatitis, acute generalized exanthematous pustulosis- (AGEP-) like patterns, and EM-like patterns-might appear in a single biopsy specimen, suggesting the diagnosis and severe cutaneous manifestations of DRESS. Cutaneous dendritic cells may be involved in the clinical course. AGEP typically shows spongiform superficial epidermal pustules accompanied with edema of the papillary dermis and abundant mixed perivascular infiltrates. Mutations in IL36RN may have a definite effect on pathological similarities between AGEP and generalized pustular psoriasis.
Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art

Thawinee Jantararoungtong,Therdpong Tempark,Napatrupron Koomdee,Sadeep Medhasi,Chonlaphat Sukasem

DOI: https://doi.org/10.1080/17425255.2021.1946514

2021-07-08

Abstract:Introduction: Pharmacogenomics has great potential in reducing drug-induced severe cutaneous adverse drug reactions (SCARs). Pharmacogenomic studies have revealed an association between HLA genes and SCARs including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).Areas covered: Pharmacogenomics-guided therapy could prevent severe drug hypersensitivity reactions. The US Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), and Dutch Pharmacogenetics Working Group (DPWG) provided guidelines in the translation of clinically relevant and evidence-based SCARs pharmacogenomics research into clinical practice. In this review, we intended to summarize the significant HLA alleles associated with SCARs induced by different drugs in different populations. We also summarize the SCARs associated with genetic and non-genetic factors and the cost-effectiveness of screening tests.Expert opinion: The effectiveness of HLA screening on a wider scale in clinical practice requires significant resources, including state-of-the-art laboratory; multidisciplinary team approach and health care provider education and engagement; clinical decision support alert system via electronic medical record (EMR); laboratory standards and quality assurance; evidence of cost-effectiveness; and cost of pharmacogenomics tests and reimbursement.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
The importance of left ventricular geometry in hypertensive heart disease.

T. Kahan,H. Persson

DOI: https://doi.org/10.1097/HJH.0000000000000557

IF: 4.9

2015-04-01

Journal of Hypertension

Abstract:S igns of hypertensive heart disease are early and important findings in patients with hypertension, and may have direct pathophysiological implications in the progression from early hypertension to cardiovascular morbidity and mortality [1,2]. There are several determinants for the development of left ventricular hypertrophy. Haemodynamic factors such as blood pressure, large artery structure and stiffness, and volume load are important. Also nonhaemodynamic mechanisms such as trophic factors mediated by the sympathetic nervous system, the renin–angiotensin–aldosterone system, and other neurohormonal mediators play an important role in the development of left ventricular hypertrophy [3]. Aside from the accelerated atherosclerotic process of coronary artery disease by elevated blood pressure, cardiac hypertrophy will cause microcirculatory alterations and impaired coronary flow reserve, and promote myocardial ischemia in hypertensive heart disease. An increased afterload will also induce cardiomyocyte hypertrophy, stimulate fibroblasts and increase collagen formation, and cause remodelling of the myocardium with an increase in myocardial fibrosis. Cardiomyocyte hypertrophy will impair systolic contractility and diastolic filling, causing left ventricular systolic and diastolic dysfunction. Myocardial fibrosis will contribute to impaired coronary flow reserve and diastolic dysfunction, and will alter electrical conduction properties with an increased risk for arrhythmias [4–6]. It has long been established that left ventricular hypertrophy by electrocardiography is a strong and independent risk factor for cardiovascular morbidity and mortality, and all-cause mortality in the general population and in patients with hypertension or coronary artery disease [7,8]. Of note, left ventricular hypertrophy can occur through wall thickening or chamber dilatation, and determination of left ventricular mass by echocardiography or MRI techniques
Quantitative analysis of DNA‐protein interactions using double‐labeled native gel electrophoresis and fluorescence‐based imaging

J. Forwood,D. Jans

DOI: https://doi.org/10.1002/elps.200500872

2006-08-01

Electrophoresis

Abstract:We have developed a sensitive, non‐radioactive method to assess the interaction of transcription factors/DNA‐binding proteins with DNA. We have modified the traditional radiolabeled DNA gel mobility shift assay to incorporate a DNA probe end‐labeled with a Texas‐red fluorophore and a DNA‐binding protein tagged with the green fluorescent protein to monitor precisely DNA‐protein complexation by native gel electrophoresis. We have applied this method to the DNA‐binding proteins telomere release factor‐1 and the sex‐determining region‐Y, demonstrating that the method is sensitive (able to detect 100 fmol of fluorescently labeled DNA), permits direct visualization of both the DNA probe and the DNA‐binding protein, and enables quantitative analysis of DNA and protein complexation, and thereby an estimation of the stoichiometry of protein‐DNA binding.
Efficient modeling of a small circular loop coupling to multi-conductor transmission lines above a PEC ground

Yifeng Qin,D. Brocker,P. Werner,D. Werner,Chenming Zhou

DOI: https://doi.org/10.1109/APS.2016.7696695

2016-06-01

Abstract:A low-frequency coupling model from a small circular loop antenna to a multi-conductor transmission line (TL) system composed of N perfect electric conductor (PEC) wires above a PEC ground is presented. The telegrapher's equations for the model are presented, and a computationally efficient analytical solution for the induced current distributions is formulated for each wire. An example is constructed in FEKO and the induced currents are compared with the proposed method, showing excellent agreement.
Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System

Hannah Godfrey,Patrick Jedlowski,Rebecca Thiede

DOI: https://doi.org/10.1111/ajd.14262

2024-04-06

Australasian Journal of Dermatology

Abstract:Background/Objectives The immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the severity of these reactions and growing association with the ICIs, their specific risk and mortality rates have been largely unexplored. Methods A case/non‐case analysis was performed using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to examine the reporting odds ratios (RORs) for ICI‐associated SCARs cases under two conditions: (1) ICIs compared with all drugs in FAERS and (2) ICIs compared with a reference group of pooled anticancer drugs to control for underlying malignancy. Results A statistically significant ROR for SJS (ROR: 5.44), TEN (ROR: 5.81) and DRESS (ROR: 1.38) were identified under Condition 1. Under Condition 2, this significance was maintained for SJS (ROR: 7.31), TEN (ROR: 7.40) and DRESS (ROR: 3.90), and mild significance was identified for AGEP (ROR: 1.89). Mortality rates for the ICIs were increased compared with the anticancer medications (28.5% vs. 24.5% for SJS, 55.3% vs. 46% for TEN, 3.0% vs. 2.1% for AGEP and 7.1% vs. 6.1% for DRESS). Conclusions Our results suggest an association between SCARs and the ICIs independent of cancer status.

dermatology
Epidemiology of cutaneous adverse drug reactions

M Mockenhaupt

DOI: https://doi.org/10.5414/ALX01508E

2017-08-04

Abstract:Epidemiologic investigation of cutaneous adverse drug reactions (cADRs) is important in order to evaluate their impact on dermatology and health care in general as well as their burden on affected patients. Few epidemiologic studies have been performed on frequent non-life-threatening cADR, including reactions of both delayed and immediate hypersensitivity, such as maculopapular exanthema (MPE), fixed drug eruption, and urticaria. Concerning rare but life-threatening severe cutaneous adverse reactions, e.g., toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), several epidemiologic studies have been performed to date, some of which are still ongoing. Such studies enable the calculation of reliable incidence rates and demographic data, and also allow researchers to perform risk estimation for drugs. The spectrum of drugs causing cADR differs substantially when separating the various clinical conditions. Whereas antibiotics are by far the most frequent inducers of milder cADRs, like MPE, they have a much lower risk of inducing SJS/TEN, for which "high-risk" drugs are anti-infective sulfonamides, allopurinol, certain anti-epileptic drugs, nevirapine, and non-steroidal anti-inflammatory drugs (NSAIDs) of the oxicam-type. In contrast, AGEP is predominantly caused by the antibiotics pristinamycin and aminopenicillins, followed by quinolones, (hydroxy-)chloroquine, and sulfonamides. DRESS can be induced by a number of drugs known to cause SJS/TEN, such as certain antiepileptics and allopurinol, but also other medications (e.g., minocyclin).
Biocompatible materials from regenerated silk for tissue engineering and medicinal therapy

A. Kon’kov,O. Pustovalova,I. Agapov

DOI: https://doi.org/10.1134/S0003683810080028

2010-11-14

Applied Biochemistry and Microbiology

Abstract:
High-risk drug rashes

Sasha A Alvarado,Diana Muñoz-Mendoza,Sami L Bahna

DOI: https://doi.org/10.1016/j.anai.2018.05.022

Abstract:Objective: To provide a brief overview of the clinical presentation, common offending agents, management, prognosis, and mortality of 6 selected high-risk drug rashes, namely, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, multiple drug hypersensitivity (MDH) syndrome, acute generalized exanthematous pustulosis (AGEP), and drug-induced bullous pemphigoid (DIBP). Data sources: A review of the published literature was performed with PubMed and supplemented with our clinical experience. Study selections: The most recent clinically relevant studies and older seminal works were selected. Results: Most of the published data on these uncommon rashes were based on small observational series or case reports. SJS and TEN have specific genotypes association with certain drugs, have high morbidity and mortality, and require aggressive management by a team of multiple specialists. DRESS syndrome is a severe, prolonged multiorgan reaction, yet it has a better prognosis than TEN. MDH is a syndrome of repeated reactions to unrelated drugs that often imposes diagnostic and management difficulties. AGEP consists of generalized sterile small pustules, usually mistaken for infection with subsequent inappropriate treatment. Bullous pemphigoid presents with tense pruritic bullae and characteristic linear basement membrane deposition of IgG and C3. DIBP has much better prognosis than the autoimmune variety. Conclusion: In such high-risk drug rashes, early recognition, immediate withdrawal of the suspected drug(s), prompt individualized management, and monitoring of vital organs function are mandatory for reducing morbidity and mortality. The lack of reliable tests for identification of the causative agent imposes difficulty, particularly in patients receiving multiple medications.
Allergic Contact Dermatitis in Psoriasis Patients: Typical, Delayed, and Non-Interacting.

Maria Quaranta,Stefanie Eyerich,Bettina Knapp,Francesca Nasorri,Claudia Scarponi,Martina Mattii,Natalie Garzorz,Anna T Harlfinger,Teresa Jaeger,Martine Grosber,Davide Pennino,Martin Mempel,Christina Schnopp,Fabian J Theis,Cristina Albanesi,Andrea Cavani,Carsten B Schmidt-Weber,Johannes Ring,Kilian Eyerich

DOI: https://doi.org/10.1371/journal.pone.0101814

IF: 3.7

2014-01-01

PLoS ONE

Abstract:Psoriasis is characterized by an apoptosis-resistant and metabolic active epidermis, while a hallmark for allergic contact dermatitis (ACD) is T cell-induced keratinocyte apoptosis. Here, we induced ACD reactions in psoriasis patients sensitized to nickel (n = 14) to investigate underlying mechanisms of psoriasis and ACD simultaneously. All patients developed a clinically and histologically typical dermatitis upon nickel challenge even in close proximity to pre-existing psoriasis plaques. However, the ACD reaction was delayed as compared to non-psoriatic patients, with a maximum intensity after 7 days. Whole genome expression analysis revealed alterations in numerous pathways related to metabolism and proliferation in non-involved skin of psoriasis patients as compared to non-psoriatic individuals, indicating that even in clinically non-involved skin of psoriasis patients molecular events opposing contact dermatitis may occur. Immunohistochemical comparison of ACD reactions as well as in vitro secretion analysis of lesional T cells showed a higher Th17 and neutrophilic migration as well as epidermal proliferation in psoriasis, while ACD reactions were dominated by cytotoxic CD8+ T cells and a Th2 signature. Based on these findings, we hypothesized an ACD reaction directly on top of a pre-existing psoriasis plaque might influence the clinical course of psoriasis. We observed a strong clinical inflammation with a mixed psoriasis and eczema phenotype in histology. Surprisingly, the initial psoriasis plaque was unaltered after self-limitation of the ACD reaction. We conclude that sensitized psoriasis patients develop a typical, but delayed ACD reaction which might be relevant for patch test evaluation in clinical practice. Psoriasis and ACD are driven by distinct and independent immune mechanisms.
Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic

Galina Balakirski,Hans F Merk

DOI: https://doi.org/10.1080/15569527.2017.1319379

Abstract:Important changes in the understanding and management of drug hypersensitivity reactions during the last years result from the increasing importance of biologics in medical practice, which differ in their spectrum of adverse drug reactions (ADRs) from the classical covalent drugs. With regard to covalent drugs, ampicillin and amoxicillin as well as clavulanic acid play an increasing role among ADRs to betalactam antibiotics. Fluoroquinolones are mainly the cause of anaphylactic and photosensitivity reactions. Especially in allergic reactions to NSAIDs, pseudoallergic reactions should be considered in the differential diagnosis. In opposite to the main cutaneous allergic drug reactions such as urticaria or maculopapular skin rash, in which antibiotics are the main culprits, in severe drug allergic reactions such as SJS (Stevens-Johnson Syndrome), TEN (Toxic Epidermal Necrolysis), or DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Syndrome, compounds like allopurinol and anticonvulsants are the main causes. Similar mutations in the IL36R gene, which were found in both patients with an AGEP (Acute Generalized Exanthematous Pustulosis) and pustular psoriasis, make the differential diagnosis more difficult and raise the question whether there is a difference between these diseases or whether AGEP is not just a drug induced pustular psoriasis. Finally, some special aspects of side effects of biologics and targeted therapies respectively are discussed.
In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals—A Systematic Review

Marina Aparicio-Soto,Caterina Curato,Franziska Riedel,Hermann-Josef Thierse,Andreas Luch,Katherina Siewert

DOI: https://doi.org/10.3390/cells11010083

IF: 6

2021-12-28

Cells

Abstract:Background: Chemical allergies are T cell-mediated diseases that often manifest in the skin as allergic contact dermatitis (ACD). To prevent ACD on a public health scale and avoid elicitation reactions at the individual patient level, predictive and diagnostic tests, respectively, are indispensable. Currently, there is no validated in vitro T cell assay available. The main bottlenecks concern the inefficient generation of T cell epitopes and the detection of rare antigen-specific T cells. Methods: Here, we systematically review original experimental research papers describing T cell activation to chemical skin sensitizers. We focus our search on studies published in the PubMed and Scopus databases on non-metallic allergens in the last 20 years. Results: We identified 37 papers, among them 32 (86%) describing antigen-specific human T cell activation to 31 different chemical allergens. The remaining studies measured the general effects of chemical allergens on T cell function (five studies, 14%). Most antigen-specific studies used peripheral blood mononuclear cells (PBMC) as antigen-presenting cells (APC, 75%) and interrogated the blood T cell pool (91%). Depending on the individual chemical properties, T cell epitopes were generated either by direct administration into the culture medium (72%), separate modification of autologous APC (29%) or by use of hapten-modified model proteins (13%). Read-outs were mainly based on proliferation (91%), often combined with cytokine secretion (53%). The analysis of T cell clones offers additional opportunities to elucidate the mechanisms of epitope formation and cross-reactivity (13%). The best researched allergen was p-phenylenediamine (PPD, 12 studies, 38%). For this and some other allergens, stronger immune responses were observed in some allergic patients (15/31 chemicals, 48%), illustrating the in vivo relevance of the identified T cells while detection limits remain challenging in many cases. Interpretation: Our results illustrate current hardships and possible solutions to monitoring T cell responses to individual chemical skin sensitizers. The provided data can guide the further development of T cell assays to unfold their full predictive and diagnostic potential, including cross-reactivity assessments.

cell biology

Treatment of chronic fistula-in-ano using commercial fibrin glue.

In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions

Delayed Skin Testing for Systemic Medications: Helpful or Not?

Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9‐year experience in a tertiary care paediatric hospital setting

Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist?

Medication Associations with Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System

Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions

Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art

The importance of left ventricular geometry in hypertensive heart disease.

Quantitative analysis of DNA‐protein interactions using double‐labeled native gel electrophoresis and fluorescence‐based imaging

Efficient modeling of a small circular loop coupling to multi-conductor transmission lines above a PEC ground

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System

Epidemiology of cutaneous adverse drug reactions

Biocompatible materials from regenerated silk for tissue engineering and medicinal therapy

High-risk drug rashes

Allergic Contact Dermatitis in Psoriasis Patients: Typical, Delayed, and Non-Interacting.

Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic

In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals—A Systematic Review